论文部分内容阅读
目的探讨在类风湿性关节炎的临床治疗过程中抗环瓜氨酸多肽(CCP)抗体的研究和应用价值。方法选取2014年3月至2015年3月收治的类风湿性关节炎患者90例作为类风湿病组,另选取其他风湿病患者90例作为风湿对照组和正常健康体检者90例作为正常对照组。记录所有入选对象的实验室检测资料并进行对比研究。结果风湿对照组、类风湿病组、正常对照组抗环瓜氨酸多肽抗体的阳性检出率分别为74.44%、5.56%、0,差异有统计学意义(P<0.05)。对类风湿关节炎的敏感性进行比较,抗环瓜氨酸多肽抗体为74.44%,类风湿因子为76.67%,差异未见统计学意义(P>0.05)。抗环瓜氨酸多肽抗体对类风湿关节炎的特异性与类风湿因子比较差异有统计学意义(P<0.05)。结论抗环瓜氨酸多肽抗体对类风湿关节炎的敏感性与类风湿因子比较差异未见统计学意义,其特异性强,可以作为临床类风湿关节炎早期诊断和预后的重要指标。
Objective To study the anti-cyclic citrullinated peptide (CCP) antibody in the clinical treatment of rheumatoid arthritis and its clinical value. Methods Ninety patients with rheumatoid arthritis who were treated in March 2014 to March 2015 were selected as rheumatoid arthritis patients. 90 other rheumatoid arthritis patients and 90 healthy volunteers were selected as normal control group . Record all the selected laboratory test data and conduct comparative studies. Results The positive rates of anti-cyclic citrulline peptide antibody in the rheumatoid control group, rheumatoid arthritis group and normal control group were 74.44%, 5.56%, 0 respectively, with statistical significance (P <0.05). The sensitivity of rheumatoid arthritis compared anti-cyclic citrullinated peptide antibody was 74.44%, rheumatoid factor was 76.67%, the difference was not statistically significant (P> 0.05). Anti-cyclic citrullinated peptide antibody specificity of rheumatoid arthritis and rheumatoid factor difference was statistically significant (P <0.05). Conclusion The anti-cyclic citrullinated peptide antibodies have no significant difference between rheumatoid arthritis and rheumatoid arthritis, and their specificity is strong, which can be used as an important index for the early diagnosis and prognosis of clinical rheumatoid arthritis.